Targeting mitochondrial dysfunction in diseases and aging
The loss of mitochondrial function will cause the progressive decline of cell activity, and even cause cell death, causing aging and disease.
For the prevention of diseases and the protection of mitochondria, mitochondrial activating factors can be supplemented by nutrition to optimize mitochondria activity and achieve the health care effect of mitochondria. In addition, for the treatment of mitochondria-related disease, mitochondrial recombination therapy can be used to replace the damaged mitochondria with exogenous high-activity and high-quality mitochondria, so that the cells return to their physiological function and back to the young state. On the other hand, in the application of stem cell therapy, the patented technology is used to strengthen the mitochondria of stem cells that enhances mitochondrial function, optimizes the activity of stem cells, and improves the quality of stem cell treatment. Through the above methods, we can achieve the prevention of aging and treatment of mitochondria-related disease for mitochondrial health care.
Mitochondrial activating factor
MitoBio is a mitochondria biologics, which are isolated and purified from good quality cells, can be administrated into damaged cells through endocytosis, and then recovered the cells by mechanism of fusion, fission, and mitophagy. It has been proved to have high-value applications in Parkinson's disease, stroke, lung injury (ARDS), myocardial infarction, infertility, and mitochondrial disease (MERRF).
Not long ago, Harvard University and Boston Children's Hospital have completed the first phase of clinical trials for congenital heart disease, which have excellent treatment outcome. Congenital heart disease with 65% mortality rate, which manifests cardiac arrest, and myocardial necrosis due to prolonged hypoxia, usually lead to organ failure and transplant. In this clinical study, mitochondria derived from skeletal muscle were injected into the heart and some functions of the heart were successfully restored. 11 infants were treated, and 8 of them recovered well. Taken together, we can see the great potential of mitochondria as biologics to treat the disease with impaired mitochondria.
Mitochondrial activated stem cells(Mitocell)
MitoCell is a stem cell product with high-quality mitochondria, which manufacture by unique culture methods and culture reagents. MitoCell has a much better expansion rate, more abundant cytokines, and better mitochondria function than normal stem cells. In our pre-clinical studies, MitoCell increases the efficacy by about 40% compared with normal stem cells. It can be applied to the treatment of diseases such as Parkinson's disease, dementia, neurodegeneration, myocardial infarction, lung injury, diabetes, liver cirrhosis, degenerative arthritis, renal failure, tendon injury, autoimmune diseases and other diseases.
Mitochondrial activated immune cells(MAKcell)
MAKcell is a kind of immunocytes with both innate and adaptive immunity. MAKcell has excellent mitochondrial function through culturing in our patented manufacturing process which makes them have more effective killing of pathogens and better interact activities with other immune cells. MAKcell is an autologous treatment that cultures the cells of our immune system to has better paracrine secretion ability and cytotoxicity of cancer.
Mitochondrial damage is an important phenomenon with age, driving cells degeneration and lesions. At present, the clinical trial of MitoCell has entered the clinical phase I for the treatment of neurodegenerative disease such as Parkinson's disease. MitoBio has been used to treat acute respiratory distress syndrome (ARDS) and macular degeneration (AMD) in preclinical research, and that has been demonstrated by in vitro and in vivo experiments.
Parkinson’s Disease (PD)
There are no effective treatments for Parkinson’s disease.
Clinical symptoms include tremors, impaired balance, and ultimately inability to walk and stand.
Approximately 10 million people worldwide are estimated to have PD, and the incidence of PD increases with age: while PD affects 1 percent of the population over the age of 60, this increases to 5 percent of the population over the age of 85 A total market size of treatment of Parkinson’s disease reached $18.379 billion USD in 2017.
Acute Respiratory Distress Syndrome (ARDS)
ARDS is the most common cause of death among ICU patients.
Clinical symptoms include poor oxygenation, lung infiltration and lung damage.
In the United States, there is an incidence of 64.2-78.9 per 100,000 people, which has a mortality rate of 45%.
There is currently no effective way to improve fibrosis due to lung injury.
Age-related Macular Degeneration (AMD)
There are no effective treatments for AMD.
Clinical symptoms include blurred vision or no vision in the center of the visual field, and that ultimately lead to blindness.
At present, about 6.2 million people worldwide are affected by AMD, and the proportion of AMD continues to increasewith age.
The market size of AMD treatment is expected to reach $ 8.9 billion by 2020.
1. International certification of Mitochondrial function testing laboratory (TAF 3232)
2. International certification for mitochondrial activated stem cell processing technology services (ISO 9001:2015 TW17/01195)
3. Innovative biotechnology and new drug research projects (Taiwan Ministry of Economic Affairs, No. 10620421210)
4. Clinical treatment of respiratory failure in pneumonia (Taiwan TFDA, No. 1071607819)
5. TFDA GTP inspection of cellular manufactory (Taiwan TFDA, No. 1071106719)
6. A Phase I Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MitoCell Transplantation in Subjects with Idiopathic Parkinson’s Disease (IRB 107-205-A)
7. International quality gold and silver awards (Monde Selection 2017, 2018, 2019)
8. International high quality trophy (Monde Selection 2019)